Propanc Biopharma Inc
OTC:PPCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Propanc Biopharma Inc
Operating Income
Propanc Biopharma Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Propanc Biopharma Inc
OTC:PPCB
|
Operating Income
-$1.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$73.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Operating Income
-AU$8.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$30.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$46.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
|
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is an approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. PRP is a therapy based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas and could represent the body’s primary defense against cancer.
See Also
What is Propanc Biopharma Inc's Operating Income?
Operating Income
-1.5m
USD
Based on the financial report for Jun 30, 2024, Propanc Biopharma Inc's Operating Income amounts to -1.5m USD.
What is Propanc Biopharma Inc's Operating Income growth rate?
Operating Income CAGR 3Y
5%
Over the last year, the Operating Income growth was 14%. The average annual Operating Income growth rates for Propanc Biopharma Inc have been 5% over the past three years .
